Modifi Biosciences Acquired by Merck
23 oct. 2024 07h05 HE
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...
Cybrexa Regains Rights to CBX-12
06 févr. 2024 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Modifi Bio Raises Additional $4.3 Million in Seed Funding
16 oct. 2023 07h00 HE
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second...
Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model at 35th AACR-NCI-EORTC Symposium
10 oct. 2023 08h05 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
04 oct. 2023 05h57 HE
|
The Insight Partners
Pune, India, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and...
Prostate Cancer Therapeutics Market Projected to Grow at 6.9% CAGR, Reaching USD 21.7 Billion by 2031: TMR Study
10 juil. 2023 05h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, July 10, 2023 (GLOBE NEWSWIRE) -- The global prostate cancer therapeutics market is projected to expand at a CAGR of 6.9% from 2022 to 2031 to reach US$ 21.7 Bn...
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
25 mai 2023 17h01 HE
|
Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Small Cell Lung Cancer Therapeutics Market Value to Exceed of USD 12.9 Bn by 2031, rising at a 11.9% CAGR: TMR Report
05 mai 2023 12h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global small cell lung cancer therapeutics market was valued at USD 4.6 Bn in 2022 and is projected to expand at a CAGR of...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12 avr. 2023 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Breast Cancer Therapeutics Market Exhibits 13.1% CAGR to hit USD 55.27 Billion by 2027
23 févr. 2023 00h45 HE
|
Fortune Business Insights
Pune, India, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The global Breast Cancer Therapeutics Market size was valued at USD 21.58 billion in 2019. The market is projected to grow USD 55.27 billion by 2027,...